Magenta Therapeutics, Inc. (MGTA) Social Stream
Magenta Therapeutics Inc (MGTA) Price Targets From Analysts
Use the tables below to see what analysts covering Magenta Therapeutics Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 13 months, MGTA's average price target has gone down $5.
Over the past 46 weeks, MGTA's average upside potential has been 147.46%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
MGTA Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
MGTA's average broker recommendation rating worsened by 0.07 over the prior 90 days.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, Magenta Therapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 749.01% of them.
- To contextualize these metrics, consider that out of all US stocks, Magenta Therapeutics Inc's variance in analysts' estimates is lower than -610.17% of them.
- In terms of how Magenta Therapeutics Inc fares relative to all US stocks, note that its average analyst price target is higher than 108.56% of that group.
- Magenta Therapeutics Inc's number of analysts covering the stock is greater than 581.83% of stocks in the small market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Magenta Therapeutics Inc are MEIP, MBIO, and MACK.
Make investment decisions regarding MGTA using the data that counts. Try POWR Ratings for free.